Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Rattus norvegicus | Vasopressin V1a receptor | Starlite/ChEMBL | References |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Schistosoma japonicum | ko:K04136 adrenergic receptor, alpha 1b, putative | Vasopressin V1a receptor | 424 aa | 400 aa | 21.8 % |
Loa Loa (eye worm) | hypothetical protein | Vasopressin V1a receptor | 424 aa | 382 aa | 22.8 % |
Onchocerca volvulus | Vasopressin V1a receptor | 424 aa | 347 aa | 21.9 % | |
Schistosoma japonicum | ko:K04209 neuropeptide Y receptor, invertebrate, putative | Vasopressin V1a receptor | 424 aa | 348 aa | 21.6 % |
Schistosoma japonicum | ko:K04135 adrenergic receptor, alpha 1a, putative | Vasopressin V1a receptor | 424 aa | 373 aa | 24.9 % |
Onchocerca volvulus | Vasopressin V1a receptor | 424 aa | 378 aa | 21.4 % | |
Echinococcus multilocularis | rhodopsin orphan GPCR | Vasopressin V1a receptor | 424 aa | 370 aa | 21.9 % |
Schistosoma mansoni | biogenic amine (5HT) receptor | Vasopressin V1a receptor | 424 aa | 347 aa | 23.9 % |
Echinococcus multilocularis | neuropeptides capa receptor | Vasopressin V1a receptor | 424 aa | 462 aa | 19.5 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Mycobacterium ulcerans | enoyl-(acyl carrier protein) reductase | 0.0361 | 0.5 | 0.5 |
Toxoplasma gondii | enoyl-acyl carrier reductase ENR | 0.0361 | 0.5 | 0.5 |
Mycobacterium tuberculosis | NADH-dependent enoyl-[acyl-carrier-protein] reductase InhA (NADH-dependent enoyl-ACP reductase) | 0.0361 | 0.5 | 0.5 |
Plasmodium vivax | enoyl-acyl carrier protein reductase | 0.0361 | 0.5 | 0.5 |
Mycobacterium leprae | NADH-DEPENDENT ENOYL-[ACYL-CARRIER-PROTEIN] REDUCTASE INHA (NADH-DEPENDENT ENOYL-ACP REDUCTASE) | 0.0361 | 0.5 | 0.5 |
Trichomonas vaginalis | hypothetical protein | 0.0361 | 0.5 | 0.5 |
Plasmodium falciparum | enoyl-acyl carrier reductase | 0.0361 | 0.5 | 0.5 |
Wolbachia endosymbiont of Brugia malayi | enoyl-ACP reductase | 0.0361 | 0.5 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | = 1.3 uM | Ability to displace [3H]- Arginine Vasopressin (AVP) from its specific binding sites in rat liver (V1 receptor) | ChEMBL. | 8393113 |
IC50 (binding) | = 1.3 uM | Ability to displace [3H]- Arginine Vasopressin (AVP) from its specific binding sites in rat liver (V1 receptor) | ChEMBL. | 8393113 |
IC50 (binding) | > 100 uM | Ability to displace [3H]- Arginine Vasopressin (AVP) from its specific binding sites in rat liver (V2 receptor) | ChEMBL. | 8393113 |
IC50 (binding) | > 100 uM | Ability to displace [3H]- Arginine Vasopressin (AVP) from its specific binding sites in rat liver (V2 receptor) | ChEMBL. | 8393113 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.